
Opinion|Videos|August 19, 2024
Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking ahead, what is the most critical priority to meaningfully enhance outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
The True Cost of Running a Community CAR T-Cell Program
4
Higher Weight-Adjusted Waist Index Tied to CKD Mortality, Study Finds
5





